FC
UTHR icon

Fairscale Capital’s United Therapeutics UTHR Stock Holding History

Fairscale Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6K Hold
50
– – 0.02% 240
2025
Q4 		$24.4K Hold
50
– – 0.02% 251
2025
Q3 		$21K Hold
50
– – 0.01% 273
2025
Q2 		$13.7K Hold
50
– – 0.01% 304
2025
Q1 		$15.4K Hold
50
– – 0.01% 235
2024
Q4 		$17.6K Hold
50
– – 0.02% 230
2024
Q3 		$17.9K Hold
50
– – 0.02% 229
2024
Q2 		$16.4K Buy
+50
New +$13.2K 0.01% 237

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fairscale Capital's UTHR Position: Q1 2026 in Review

Fairscale Capital held its United Therapeutics (UTHR) position steady in Q1 2026 at 50 shares worth $29.6K. The position accounts for 0.02% of the portfolio, ranked #240.

Fairscale Capital first reported a position in UTHR in Q2 2024 and has held it in 8 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Fairscale Capital held 50 shares of United Therapeutics worth $29.6K as of Q1 2026.
  • Fairscale Capital left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up 0.02% of Fairscale Capital's portfolio in Q1 2026, its #240 holding.
  • Fairscale Capital first reported a position in United Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Fairscale Capital's 13F filing for Q1 2026, filed 11 May 2026.